For adult and pediatric patients with hemophilia A
AFSTYLA, with twice-weekly dosing available, delivers long-lasting bleed protection using a novel single-chain design
Enhanced von Willebrand
factor affinity extends time
Have a CSL Behring representative contact you or sign up for updates and information about AFSTYLA
A My SourceSM Care Coordinator is standing by—Monday through Friday, 8 am to 8 pm ET—to provide you detailed information about services available to your patients.
Reference: 1. Zollner S, Raquet E, Claar P, et al. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2014;134(1):125-131.